Par Pharmaceutical
Companies, Inc. PRX announced today that it entered into a definitive
agreement to acquire Anchen Pharmaceuticals, for $410 million in cash. The transaction
is expected to be immediately accretive to non-GAAP earnings in 2011.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in